Wegovy Cost Without Insurance: Cash-Pay, NovoCare, Savings Cards, and the May 2026 Price Map

If you have no insurance coverage for Wegovy in May 2026, the cash price is $349 a month for the weekly injection pen. Novo Nordisk sets that price through its own pharmacy (NovoCare); it holds across every dose from 0.25 mg through 2.4 mg, and it is $1,000 lower than the retail list price that defined this drug for its first three years. There is also a $199 starter rate for the first two fills at the two lowest doses, and a separate savings card for commercially insured patients. In early 2026 Novo launched an oral Wegovy pill with a lower cash-pay entry point: $149 a month for the two lower pill doses. We don't sell Wegovy and have no affiliate relationship with Novo Nordisk.

The headline May 2026 price

Novo Nordisk announced the current pricing in a press release on November 17 2025. The standard monthly cash-pay price fell from $499 to $349. Alongside the cut, Novo introduced a $199-a-month introductory rate at the 0.25 mg and 0.5 mg starter doses, good for the first two fills. The press release framed the $199 offer as running through March 31 2026; the NovoCare pricing page has since extended it through June 30 2026.

CNBC's coverage read the move as Novo's response to a narrowing price gap with compounded semaglutide and growing political attention to GLP-1 list prices. The effective price for a cash-paying US patient in May 2026 is $349 a month, with a one-time discount on the way in. The HD 7.2 mg pen, a separately approved higher-strength presentation, runs $399.

The oral Wegovy pill: a lower cash-pay entry point

In early 2026 Novo Nordisk launched the oral Wegovy pill, a daily semaglutide tablet that delivers the same active molecule as the injection. The NovoCare cash-pay price for the pill is structured differently from the pen:

The pill requires taking it on an empty stomach and waiting 30 minutes before eating or taking other medications, because oral semaglutide absorption is sensitive to food and other drugs. For patients who prefer to avoid weekly injections, the $149 entry price is a meaningful alternative to the $349 injection route — though the escalation to higher pill doses closes much of that gap.

One note from patients already using it: a commenter in r/Semaglutide wrote that they switched from the Wegovy injection to the pill after insurance dropped coverage, describing it as "getting the new Wegovy pill through NovoCare since it's the cheapest option out of pocket" — at $300 a month for the higher dose they moved to. That matches the $299 price for the 9 mg tier.

The NovoCare Pharmacy pathway

NovoCare Pharmacy is Novo Nordisk's own direct-to-patient pharmacy, launched in March 2025 to give uninsured and underinsured patients a stable cash-pay route. It is the channel that dispenses the $349 injection price and the $149–$299 pill prices.

To enrol, you need a prescription that matches the FDA-approved label criteria: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbid condition (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or established CV disease). Adolescents 12 and older with a BMI in the 95th percentile or above are also covered. The full NovoCare enrollment walkthrough covers the step-by-step process.

You can ask your prescriber to send a new prescription to NovoCare, or transfer an existing one. NovoCare ships to your home at no charge on a 28-day cadence. The cash price is the same on every fill: no first-fill surcharge, no annual reset, no specialty add-on. All injectable doses are available (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, and 7.2 mg), as are all four oral pill doses (1.5 mg, 4 mg, 9 mg, and 25 mg).

If your insurance covers Wegovy, you'd typically use the savings card below; if it doesn't, NovoCare is the path.

The savings card

The Wegovy savings card is Novo's commercial-insurance offer. It is separate from NovoCare cash pay; the two cannot be stacked.

Per the program terms, a commercially insured patient whose plan covers Wegovy can pay as little as $25 a month out of pocket, with the card covering up to $100 per fill. Patients on commercial plans that don't cover Wegovy can use a separate version for a smaller reduction, though for that population NovoCare's $349 is usually simpler.

The exclusions matter. The card is closed to anyone enrolled in Medicare (including Part D), Medicaid, TRICARE, the VA, or any federal or state pharmacy benefit program. That is a federal anti-kickback rule, not a Novo policy choice, with no workaround. If you are on Medicare Part D, the card cannot be used even if your plan covers Wegovy.

Card terms are subject to change. We last verified the $25 figure and $100 cap on the NovoCare site in May 2026.

The pharmacy list-price route

Before the cash-pay programs existed, Wegovy was sold at a list price of about $1,349 a month at retail pharmacies. That figure, confirmed in trade-press coverage of Novo's March 2025 cut, defined the cost conversation about this drug from 2021 through early 2025. It also drove the compounded-semaglutide market: a $200-a-month compounded equivalent was a tenth the price.

Novo cut the cash route in stages. The first $499 direct-ship offer landed in March 2025 alongside the NovoCare launch. In autumn 2025, Novo extended the $499 price to retail pharmacies. The drop to $349 followed on November 17 2025.

For a cash-paying patient in May 2026, the retail-pharmacy list price is usually the wrong answer. It is still what your local CVS or Walgreens will quote if you walk in without insurance and don't ask for the cash-pay program. Asking whether the Novo cash-pay price applies at that store, or routing through NovoCare directly, is what gets you to $349. If a retail pharmacy quotes $1,349, switch routes rather than pay.

Insurance versus cash-pay arithmetic

Three patient profiles capture most of the live cases we see in 2026.

Profile A: employer plan that excludes weight-loss drugs. Most large employer plans still exclude anti-obesity drugs as of 2026. If yours does, NovoCare's $349 is the floor. Verify whether the exclusion is blanket or drug-specific, and whether there is a cardiovascular-prevention pathway for patients with established CV disease. The latter sometimes restores coverage for the narrow subset whose prescriber documents the CV indication. If you face a denial, see our prior authorization appeal guide for the step-by-step process.

Profile B: self-employed on a high-deductible health plan. HDHPs typically run a $3,000 to $8,000 individual deductible. If your HDHP includes Wegovy on its formulary, the gross drug cost bills against your deductible. The savings card's $25-a-month rate brings cash out-of-pocket below NovoCare's $349, but the full drug cost still accumulates toward your deductible. If you're likely to hit it anyway that's a benefit; if not, NovoCare is simpler.

Profile C: Medicare Part D enrolment. Medicare covers semaglutide for type 2 diabetes (under the Ozempic brand) and for established cardiovascular disease in adults with overweight or obesity (the Wegovy CV indication added in 2024). It does not cover Wegovy for weight management alone. If your prescription is written for weight management without a CV indication, the savings card is closed and NovoCare is your route. If it is written under the CV indication, your Part D copay applies and the savings card still cannot be used. See our guide on how to get a GLP-1 prescription and the cheap GLP-1 alternatives page if cost remains a barrier.

Whichever profile applies, ask what your specialty-drug deductible looks like and whether Wegovy is tier 3, tier 4, or specialty. That determines whether cash-pay is materially cheaper than insurance.

The compounded shortcut, and why it's now mostly closed

Through 2023 and most of 2024, the dominant alternative to brand Wegovy was compounded semaglutide at $199 to $299 a month. That market existed because the FDA had declared semaglutide in shortage; once the shortage was resolved on February 21 2025, the legal authority to mass-produce compounded copies expired.

The full timeline sits in our separate compounding-cliff article. For cost, the point is that the price gap has narrowed to roughly $150 a month versus NovoCare's $349. For most patients, the regulatory complexity of the remaining personalised-dose pathway no longer justifies the saving.

What this means at the dose-escalation point

Wegovy escalates over roughly 16 weeks: 0.25 mg for four weeks, then 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Under NovoCare, the price is identical at every step: $349 a month. That flat structure is unusual for injectable specialty drugs. Your monthly budget doesn't change as you titrate up, and if you stall at a lower dose because of side effects, the cost doesn't fall but doesn't penalise you either.

The 7.2 mg HD pen is the only dose priced above $349, at $399. That step lands where most patients are also discussing whether HD's larger weight-loss effect (STEP UP put it at roughly 18.7% of body weight versus 13.7% for 2.4 mg) justifies the additional GI side-effect burden. The $50 gap is too small to be the deciding factor either way.

What to ask before paying cash for any dose

Four questions, in this order:

1. What is the refund or return policy on unused pens? If your prescriber switches you, what happens to the pens you've paid for. NovoCare's standard policy is no refund on shipped product, which is normal for injectables; confirm in writing before your first fill.
2. Does the quoted price hold if I pause therapy? Patients who pause for a month sometimes find that re-enrolment counts as a new patient, which can reset the introductory-rate clock or trigger a fresh prior authorisation.
3. Is supply shipped direct from the manufacturer or its named pharmacy? NovoCare is the only Novo-sanctioned cash-pay shipping channel in May 2026. If a provider's price is materially lower and they cannot name the source pharmacy, that is a flag.
4. Is there a documented tapering protocol when I eventually stop? The STEP 1 trial extension showed patients regained roughly two-thirds of lost weight by week 120 after stopping semaglutide. A provider that has thought about the off-ramp should be able to show you the protocol. A provider that hasn't is one that benefits from your indefinite subscription. See our off-ramp evidence summary for the published data.

What patients are actually paying: Reddit cost experiences

Three themes surface consistently in cash-pay cost discussions on r/Ozempic and r/Semaglutide in 2025–2026.

The telehealth platform fee trap. A widely-upvoted post on r/Ozempic noted that Hers (the women's platform from Hims) charges a $150-a-month access fee on top of the drug cost, bringing the minimum to roughly $348 a month — comparable to NovoCare, but with less transparency upfront. The poster's advice: get a prescription through any provider and fill it at NovoCare or a retail pharmacy with the cash-pay program, skipping the platform markup entirely. "Don't have insurance? Just get a script from your doctor for Wegovy and get it through [NovoCare] for $199," the post read (reflecting the introductory-dose price).

Savings card copay drift. Several r/Semaglutide comments in the WSJ list-price thread described out-of-pocket costs rising even as the program exists: "My out of pocket with the coupon went from $0 to $100 per month" and "My out of pocket went from $25 to $50." This reflects changes in how individual plan formularies interact with the savings card's $100-per-fill cap — the card covers up to $100 of the patient's share, but if a plan moves Wegovy to a higher tier, the patient share above $100 falls to the patient. NovoCare's flat $349 bypasses that variability entirely.

Insurance coverage denial is still common. A r/Semaglutide post from a US patient with pre-diabetes, Hashimoto's, and tachycardia described being approved for Wegovy only after "jumping significant hoops to prove myself worthy" because she was not yet diabetic. Her frustration: "insurance refusing to pay for a medication that clearly can help with things other than diabetes." For patients in similar limbo, NovoCare's no-prior-auth path is the practical alternative while coverage battles proceed.

What the 2027 list price cut means (and doesn't)

The Wall Street Journal reported in early 2026 that Novo Nordisk plans to cut the US list prices of Ozempic and Wegovy to $675 a month, effective January 1, 2027 — roughly half the current ~$1,350 list price. The cut applies to both injection and pill formulations. Critically, as multiple r/Semaglutide commenters noted, Novo confirmed the list-price cut does not change the existing NovoCare cash-pay discounted prices. What it would affect is patients on high-deductible plans paying coinsurance as a percentage of list price, and potentially how insurers price their formulary tiers. For a cash-paying uninsured patient in May 2026, the operative number remains $349 through NovoCare.

How we keep this article current

We refresh this page on any Novo pricing change, FDA action, or formulary shift that affects a US patient's out-of-pocket cost. Four things move faster than the rest:

• Novo cash pricing. It has changed twice in roughly nine months: $1,349 to $499 in March 2025, then $499 to $349 in November 2025. That cadence, plus political and competitive pressure, means the current structure is unlikely to be the last move.
• Oral pill pricing. The 4 mg dose is $149 through August 31 2026 and steps to $199 after that.
• The compounded route. FDA's April 30 2026 proposal to permanently bar semaglutide from the 503B bulk-substances list closes public comment on June 29 2026; a softening could reopen part of the compounded route. Value-based contracting is also live; if Wegovy moves to outcomes-based pricing for some commercial plans, the savings-card economics would shift.
• Medicare's posture toward weight-management coverage. Any expansion would change Profile C materially.

Companion pages: our Zepbound cost article, the compounding-cliff timeline, our methodology, and the editorial policy. If you spot a price or source that has shifted, please email [email protected]. We acknowledge corrections within five business days and publish within fifteen.